This week's top stories include breaking FDA approvals, insights on AI-assisted front desk management, and more.
|Articles|May 30, 2020
Video: Defocus Media: New cosmetic line safe for ocular surface
Author(s)Jennifer Lyerly, OD, Darryl Glover, OD
Advertisement
Jennifer Lyerly, OD, and Darryl Glover, OD, of Defocus Media talk with Leslie O'Dell, OD, FAAO, and Amy Gallant Sullivan about Ãyes are the Story, their new cosmetic line which is designed to be safe for the ocular surface.
Advertisement
Related to this article
Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using one tool consistently.
Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.
Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
More than monitoring: Using AMD visits to promote healthy vision aging
2
Study: OCTA analysis tools report different macular vessel density values for glaucoma
3
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
4
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
5